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Available online xxxxBackground: Lacunar stroke, a frequent clinical manifestation of small vessel disease (SVD), differs pathologically
from other ischaemic stroke subtypes and has no speciﬁc long-term secondary prevention. Licenced drugs,
isosorbide mononitrate (ISMN) and cilostazol, have relevant actions to prevent SVD progression.
Methods:We recruited independent patients with clinically conﬁrmed lacunar ischaemic stroke without cogni-
tive impairment to a prospective randomised clinical trial, LACunar Intervention-1 (LACI-1). We randomised pa-
tients using a centralweb-based system, 1:1:1:1withminimisation, tomasked ISMN25mgbd, cilostazol 100mg
bd, both ISMN and cilostazol started immediately, or both with start delayed. We escalated doses to target over
two weeks, sustained for eight weeks. Primary outcome was the proportion achieving target dose. Secondary
outcomes included symptoms, safety (haemorrhage, recurrent vascular events), cognition, haematology, vascu-
lar function, and neuroimaging. LACI-1was powered (80%, alpha 0.05) to detect 35% (90% versus 55%) difference
between the proportion reaching target dose on one versus both drugs at 55 patients. Registration
ISRCTN12580546.
Findings: LACI-1 enrolled 57 participants betweenMarch 2016 and August 2017: 18 (32%) females, mean age 66
(SD 11, range 40–85) years, onset-randomisation 203 (range 6–920) days. Most achieved full (64%) or over half
(87%) dose, with no difference between cilostazol vs ISMN, single vs dual drugs. Headache and palpitations in-
creased initially then declined similarly with dual versus single drugs. There was no between-group difference
in BP, pulse-wave velocity, haemoglobin or platelet function, but pulse rate was higher (mean difference, MD,
6.4, 95%CI 1.2–11.7, p = 0.02), platelet count higher (MD 35.7, 95%CI 2.8, 68.7, p = 0.03) and white matter
hyperintensities reduced more (Chi-square p = 0.007) with cilostazol versus no cilostazol.
Interpretation: Cilostazol and ISMN are well toleratedwhen the dose is escalated, without safety concerns, in pa-
tients with lacunar stroke. Larger trials with longer term follow-up are justiﬁed.
Funding: Alzheimer's Society (AS-PG-14-033).
© 2019 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Cerebral small vessel disease (SVD) is a common cause of ischaemic
(‘lacunar’) and haemorrhagic stroke, vascular andmixed dementias [1].-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Research in context
Evidence before this study
A quarter of all strokes are lacunar in type with a high risk of
cognitive decline, yet there are few trials of secondary prevention.
Conventional secondary ischaemic stroke prevention after lacunar
ischaemic stroke had limited benefit in preventing recurrent
stroke, small vessel disease progression or cognitive decline. Li-
cenced drugs which improve endothelial function, cilostazol or
isosorbide mononitrate, may be effective but lack data inWestern
populations. In Asia-Pacific countries, cilostazol reduced recurrent
stroke (five trials, 4780 patients, many with lacunar stroke, OR
0.64, 95%CI 0.51–0.79) and incident dementia (population regis-
try analysis, 9148 dementia-free subjects, adjusted HR 0.75,
95%CI 0.61–0.92, p for dose trend, 0.001). There are no data
on nitrates in secondary stroke prevention despite their wide-
spread use in cardiovascular disease.
Added value of this study
Cilostazol and isosorbide mononitrate are well tolerated indi-
vidually and together in patients with lacunar stroke, in addition
to conventional secondary stroke prevention,may improve vascu-
lar function, cognitive and neuroimaging secondary outcomes.
Implications of all the available evidence
LACI-1 supports wider testing of cilostazol and isosorbide
mononitrate to prevent worsening of cerebral small vessel dis-
ease, a common cause of stroke, cognitive decline and dementia.
2 G.W. Blair et al. / EClinicalMedicine xxx (xxxx) xxxSVD is most commonly due to an intrinsic disorder of the brain's small
perforating arterioles with endothelial dysfunction, blood–brain barrier
leakage [2], impaired vasoreactivity and inﬂammation [1].
There is currently no speciﬁc secondary prevention for lacunar isch-
aemic stroke, or SVD-associated cognitive decline [3]. Dual antiplatelet
therapy increased bleeding, and intensive antihypertensive treatment
did not reduce recurrence [4,5]. We identiﬁed two oral agents with po-
tential modifying effects on the endothelial dysfunctions mentioned
above, isosorbide mononitrate (ISMN) and cilostazol, from a detailed
systematic literature analysis [3].
ISMN is a nitric oxide (NO) donor commonly used in angina. NO
levels are reduced in acute and chronic stroke including lacunar stroke
[6]. Glyceryl trinitrate (GTN), an NO donor, improved cognitive test
scores at 90 days if givenwithin 6 h of stroke [7]. NOhasmultiple poten-
tial effects which may beneﬁt SVD, including improved blood–brain
barrier integrity, vasodilation, reducing inﬂammation, and neuroprotec-
tion [3,8]. However, data on ISMN in lacunar stroke are sparse since its
main therapeutic indication, ischaemic heart disease, is uncommon in
these patients [9].
Cilostazol is a phosphodiesterase 3′ inhibitor [3] used for peripheral
vascular disease in Europe and North America [10], and stroke preven-
tion in Asia-Paciﬁc countries where there are data from trials including
over 6000 patients showing reduction in recurrent stroke [11].
Cilostazol also hasmultiple potential beneﬁts relevant to SVD, including
improving blood–brain barrier integrity, vasodilation, reducing inﬂam-
mation, and neuroprotection [3,12]. In a large national health registry
in Taiwan, prescription of cilostazol was associated with reduced inci-
dence of dementia [13].
There is little experience of cilostazol in lacunar stroke outside the
Asia-Paciﬁc Region, of ISMN in lacunar stroke anywhere, or of thePlease cite this article as: G.W. Blair, J.P. Appleton, K. Flaherty, et al., Tolerab
isosorbide mononitra..., , https://doi.org/10.1016/j.eclinm.2019.04.001drugs in combination, yet the effects are potentially synergistic [3].
The aims of the LACunar Intervention Trial-1 (LACI-1) trial were to
test ISMN and cilostazol, alone and combined, for tolerability including
symptoms, safety, and signals for efﬁcacy (cognitive, systemic, cerebro-
vascular and haematological endpoints) after lacunar ischaemic stroke.
LACI-1 tested short-term drug administration including dose escalation
to prepare for a larger trial of longer-term drug administration with
safety and efﬁcacy outcomes.
2. Materials and Methods
LACI-1 was a Phase IIa, partial factorial, dose-escalation, prospective,
randomised, open-label, blinded endpoint (PROBE) trial conducted in
two large UK stroke centres (Edinburgh and Nottingham). The trial
was approved by the Scotland A Research Ethics Committee (Ref 15/
SS/0154), the Medicines and Healthcare Regulatory Agency (Ref
01384/0244/001-0001) and NHS R+D (Ref 2015/0354/TMF) and all
participants gave written informed consent. There were no changes to
the methods after trial commencement.
The trial was registered: ISRCTN-12580546, ClinicalTrials.gov
(NCT02481323), EudraCT (2015-001953-33). The Protocol and Statisti-
cal Analysis Plan are published [14]. LACI-1 reporting follows the
CONSORT statement.
The ﬁrst participant was recruited and randomised on 16th March
2016, the ﬁnal patient on 29th August 2017 and ﬁnal follow-up was
competed on 31 October 2017.
2.1. Patient Selection
We included patients with: clinical lacunar stroke in the past four
years with brain magnetic resonance imaging (MRI) or CT scanning ob-
tained at the presentation with stroke showing a symptomatic small
subcortical (lacunar) infarct (b20 mm), or (if no recent relevant infarct
was visible), that excluded other causes of symptoms (e.g. acute cortical
infarct, tumour); age ≥ 35 years; were independent in activities of daily
living (modiﬁed Rankin Scale of ≤2); and had capacity to give informed
consent [14]. An acute small subcortical infarct was deﬁned on CT as a
b20 mm diameter hypoattenuated area (relative to the brain, but not
as hypoattenuated as CSF) in white or deep grey matter, in a brain re-
gion correspondingwith the stroke symptoms, not present on neuroim-
aging (if available) prior to the stroke.
We excluded patients with: other active neurological illness since
the incident stroke; cognitive impairment (Montreal Cognitive Assess-
ment [MoCA] score below 20); active cardiac disease; symptomatic ca-
rotid artery stenosis N50% requiring urgent treatment; deﬁnite
contraindication to or indication for either trial drug; taking prohibited
medications that could not be changed (anticoagulants, phosphodies-
terase 5′ inhibitors, macrolides, ketoconazole, itraconazole, omepra-
zole); creatinine clearance b25 ml/min; bleeding tendency or a
history of intracranial haemorrhage; or inability to swallow [14].
2.2. Data Collection at Baseline
We collected baseline demographic, clinical and cognitive character-
istics, including minimisation variables of age ≤/N70 years, local
investigator-determined SVD severity on brain scanning (SVD score ≤/
N2) [15], systolic blood pressure ≤/N140 mm Hg and time after stroke
≤/N100 days, prior to randomisation.
2.3. Randomisation and Masking
We used a secure web-based randomisation system, hosted at the
University of Nottingham, to randomise participants 1:1:1:1 into four
groups (CONSORT Diagram, Fig. 1). We used minimisation on age,
SVD score, systolic BP, time since onset to maintain balance in baselineility, safety and intermediary pharmacological effects of cilostazol and
3G.W. Blair et al. / EClinicalMedicine xxx (xxxx) xxxvariables between the groups, and switching 5% of randomisations ran-
domly to an alternate treatment group, to reduce predictability:
1) cilostazol alone, 50mg twice daily, increasing to 100mg twice daily;
2) ISMN alone, 25 mg once daily increasing to 25 mg twice daily;
3) cilostazol and ISMN combined, started immediately, ISMN given
ﬁrst; and.
4) cilostazol and ISMN combined, start delayed for three weeks,
cilostazol given ﬁrst.
Participants allocated to both drugs aimed to attain the same target
doses as for either drug alone. Group four (delayed start, both drugs)
provided a ‘no drug’ comparison during the ﬁrst three weeks of the
trial while they received no drug.
Tomaintain blinding of participants, prior to the start of the trial, the
Investigational Supplies Group (ISG), an independent arm of the Re-
search and Development Ofﬁce, NHS Lothian, removed study medica-
tions from their original blister packs and placed them in bottles
labelled ‘Drug A’ or ‘Drug B’, a process whichwas approved by theMed-
icines and Healthcare Regulatory Agency. The labelled bottles were dis-
tributed to thehospital pharmacies at the CityHospital, Nottinghamand
the Western General Hospital, Edinburgh for storage and dispensing to
participants following randomisation.
The randomisation program provided a prescription detailing the
number of bottles of ‘Drug A’ and/or ‘Drug B’, which was dispensed by
the hospital pharmacy with instructions about dose escalation and a
diary for the participant to record their actual doses. The instructions re-
ferred to ‘Drug A’ or ‘Drug B’, not to either drug by name.Fig. 1. CONSORT diagram. ISMN
Please cite this article as: G.W. Blair, J.P. Appleton, K. Flaherty, et al., Tolerab
isosorbide mononitra..., , https://doi.org/10.1016/j.eclinm.2019.04.001Trial medication was taken for nine weeks, starting at low dose and
increasing gradually over 2–3weeks, as tolerated, to full dose, sustained
until eightweeks post-randomisation, then decreased and stopped over
one week, with a ﬁnal follow-up after two further weeks without trial
tablets [14]. We designed the escalating dose to reduce potential ad-
verse effects during cilostazol initiation (recommended where
cilostazol is more widely used in Asia-Paciﬁc countries), and escalation
is standard for ISMN. Nineweeks allowed time for dose escalation and a
period on sustained dose to evaluate tolerability since data were insuf-
ﬁcient to move directly to a trial with longer term administration. Pa-
tients returned unused tablets to pharmacy for counting and
destruction. Participants continued to take their prescribed medica-
tions, including conventional stroke prevention drugs, during the trial.
2.4. Outcomes
The primary outcome was the proportion of participants achieving
target dose by the end of the eight-week trial period, assessed by struc-
tured questionnaire, by staff masked to allocated group. Secondary out-
comes, in all participants, also by staff masked to allocated group, were:
symptoms (headache, nausea, diarrhoea, vomiting, bleeding) recorded
by structured questionnaire on alternate weeks; safety, (systemic or in-
tracranial bleeding, recurrent vascular events, death); blood pressure,
measured sitting and standing at study visits; heart rate; Trails A and
B tests for cognitive function; systemic arterial stiffness (pulse wave
analysis using the SphygmoCor tonometry device [Atcor Medical]);
and platelet function (P-selectin ﬂow cytometry) [16]. Participants re-
cruited in Edinburgh also had MR brain imaging at randomisation
using the Blood Oxygen Level Dependent (BOLD) method to assess= isosorbide mononitrate.
ility, safety and intermediary pharmacological effects of cilostazol and
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inwhite and deep greymatter, using a validated technique [17] (full de-
tails of CVR acquisition and analysis are in the Supplementarymaterial).
The CVR examination was repeated after three weeks of no drug in the
delayed start group, and at the end of the eight-week treatment period
in the other three groups, to assess if the trial treatments altered CVR.
The repeat structural scanning also allowed us to test for alterations in
white matter lesions (WML), lacunes or microbleeds between baseline
and the end of the trial.
We performed central blinded reading of the diagnostic CT and MRI
imaging to score the index infarct, SVD features and total SVD score [15],
using structured, validated tools [18]. We also assessed the structural
MR brain images, performed as part of the CVR examination, for change
in SVD lesions, new infarcts or haemorrhages occurring during the trial
[18].
2.5. Statistical Analysis and Power
We powered the LACI-1 trial to test the hypothesis that patients
would tolerate one drug better than both drugs, setting the sample
size to detect a difference of 90% versus 55% (i.e. an absolute difference
of 35%) between those reaching target (full) dose on one drug versus
both drugs. For 80% power, signiﬁcance 0.05, a sample size of 55 was
needed; therefore, we aimed to recruit 60 participants (for sample
size estimation for the CVR substudy, please see the Supplementaryma-
terial p3) [14].
In primary and secondary analyses, we compared outcomes by
treatment allocation to test cilostazol versus no cilostazol, ISMN versus
no ISMN, and both drugs versus one drug with the delayed start group
providing a drug-free control period. We calculated odds ratios (ORs)
for tablet compliance by allocated group using binary logistic regression
with adjustment forminimisation factors (age, SVD score, systolic blood
pressure and time from stroke to randomisation in days). We assessed
secondary outcomes of symptoms, safety, cognitive and physiological
measures in all, and change in CVR and in SVD lesions in patients re-
cruited in Edinburgh, using binary logistic regression for binary vari-
ables, multiple linear regression for continuous variables, Kruskal–
Wallis test for between group differences in continuous variables since
the variables were not normally distributed, and refer to mean differ-
ences (MD) where relevant. We also examined time trends over the
11 weeks of the trial in repeated measures analysis comparing delayed
versus immediate start of both drugs. All analyses were on intention to
treat, except we performed an additional secondary analysis of change
in CVR by proportion of target dose achieved.
3. Role of the Funding Source
The trial was designed, conducted, analysed, interpreted, the paper
written and submitted independently of the funders.
4. Results
Recruitment into LACI-1 began on 16th March 2016 and ended on
29th August 2017, and we randomised 57 patients, 29 in Nottingham
and 28 in Edinburgh (Fig. 1), rate 1.64 patients/centre/month (Supple-
mentary Fig. S1). The mean age was 66.1 (SD 11.1) years, 18 were fe-
male (32%), the median time from index stroke to randomisation was
203 days, 42 (74%) had hypertension, and 26 (46%) were current
smokers (Table 1). Most participants (55, 97%) were taking clopidogrel
for secondary stroke prevention and two (3%)were taking aspirin.Most
participants (80%) had a visible index infarct on their diagnostic imag-
ing (MRI in 44 (77%) and CT in 13 (23%) participants, some had both),
and 25 (44%) had moderate to severe WML.
The groupswerewell balanced for baseline characteristics except for
the participants allocated to cilostazol who were older, had higher
Fazekas scores indicating more WML, and had lower Trails B scoresPlease cite this article as: G.W. Blair, J.P. Appleton, K. Flaherty, et al., Tolerab
isosorbide mononitra..., , https://doi.org/10.1016/j.eclinm.2019.04.001respectively (Table 1). One participant withdrew at week three (de-
layed start dual drugs, prior to receiving any trial drug) and did not com-
plete that follow-up or any after; one participant missed a follow-up in
week ﬁve (ISMN group) but completed all prior and subsequent follow-
ups.4.1. Tablet Compliance
For the primary outcome, 40 (72%) were taking full (no doses
missed) or partial doses (includes missing between one and up to 50%
of allocated dose) of the allocated tablets by the end of the eight-week
treatment period, with no difference between groups (Table 2, Fig. 2;
partial dose details, Supplementary Fig. S2). Most patients who
achieved ‘partial dose’ only missed one or two doses in any assessment
period. ISMN may be tolerated better than cilostazol: 13/15 allocated
ISMN alone (87%) achieved full or partial ≥50% dose by week eight ver-
sus 9/13 (69%) allocated cilostazol alone (any ISMN versus no ISMN
achieving full dose, OR 3.77, 95%CI 0.98–14.46, p=0.053; any cilostazol
versus no cilostazol achieving full dose, OR 0.39, 95%CI 0.11–1.34, p =
0.14). Dual drugs were tolerated similarly to either individual drug:
ISMN plus cilostazol versus one or other drug alone achieving full
dose, OR 0.84, 95%CI 0.27–2.64, p = 0.77 (Table 2). Combining the full
and partial doses versus no tablets gave similar results (data not
shown). In the dual drug groups, there was no evidence that starting
with one drug produced different symptoms or tolerance than starting
with the other drug, or that those who ceased to take tablets did so be-
cause of more symptoms.4.2. Symptoms Potentially Related to Trial Medication
Symptoms were common without trial medication. In the week
prior to randomisation, the following symptoms were experienced:
headache 30%; palpitations 20%; dizziness 40%; loose stools 30%; nausea
15%; dyspepsia 45%; bruising 20%; bleeding from mucous membranes
15%; and rash 9%. Following drug initiation, there was a slight increase
in headache, palpitations, dizziness, loose stools, nausea, followed by a
return to baseline levels with continued trial drug (Fig. 3; Table 2; Sup-
plementary Fig. S3). There was no increase in dyspepsia, bruising, or
bleeding (Supplementary Fig. S3). Neither cilostazol nor ISMNwere as-
sociatedwithmore symptoms and patients allocated dual drugs did not
report more symptoms than those allocated one drug (Fig. 3; Table 2;
Supplementary Fig. S3).4.3. Secondary Outcomes, All Participants
Cognition: The points achieved on Trails A increased in the group al-
located to ISMN compared with no ISMN (MD 2.6, 95%CI 0.1, 5.1, p =
0.045), with no effect on Trails B points (MD 2.3, 95%CI−0.7, 5.3, p =
0.126) after adjustment for baseline Trails (Table 2). Participants took
less time to complete the tests in groups allocated cilostazol versus no
cilostazol, ISMN versus no ISMN, and both versus one or other drug, al-
though these differences did not reach signiﬁcance.
Blood pressure (BP) reduced during drug initiation, but with no sig-
niﬁcant difference between groups by week eight (Table 2). Heart rate
at week eight was higher in those allocated cilostazol versus no
cilostazol (MD 6.4, 95%CI 1.2–11.7, p = 0.017). Buckberg Index (suben-
docardial perfusion) was reduced at week eight with cilostazol (OR−
10.87, 95%CI −21.2, −0.5, p = 0.04) and combined cilostazol and
ISMN (OR −11.4, 95%CI −21.0, −1.7, p = 0.02). There were no
sustained changes in pulse wave velocity or Augmentation Index.
Haematology: There was no difference in haemoglobin or platelet
function between groups at the end of the treatment period (Table 2).
However, platelet count increased in those on cilostazol vs no cilostazol
(MD 35.7 95%CI 2.8, 68.7, p = 0.033).ility, safety and intermediary pharmacological effects of cilostazol and
Table 1
Baseline characteristics of patients randomised in LACI-1.
All Both delayed ISMN Cilostazol Both immediate
Patients (number) 57 15 15 13 14
Age (years)⁎ 66.1 (11.1) 63.4 (11.5) 62.2 (11.0) 75.8 (8.7) 64.4 (8.1)
Sex, female 18 (31.6%) 6 (40.0%) 4 (26.7%) 5 (38.5%) 3 (21.4%)
Onset to randomisation (days) 202.6 (256.2) 153.3 (180.4) 137.5 (214.2) 279.2 (324.7) 254.0 (290.7)
Systolic BP (mm Hg) 147.3 (20.5) 141.8 (19.6) 150.9 (19.0) 146.1 (21.3) 150.4 (22.9)
Diastolic BP (mm Hg) 83.3 (12.6) 82.9 (14.3) 86.6 (11.5) 79.3 (12.0) 83.7 (12.6)
Past medical history (%)
Treated hypertension 42 (73.7%) 11 (73.3%) 11 (73.3%) 12 (92.3%) 8 (57.1%)
Treated hyperlipidaemia 48 (84.2%) 11 (73.3%) 12 (80.0%) 13 (100.0%) 12 (85.7%)
Diabetes 11 (19.3%) 3 (20.0%) 3 (20.0%) 2 (15.4%) 3 (21.4%)
Atrial ﬁbrillation 0 0 0 0 0
Ipsilateral carotid stenosis N 50% 1 (3.1%) 0 0 1 (14.3%) 0
Myocardial infarction or angina 3 (5.3%) 2 (13.4%) 0 1 (7.7%) 0
Previous stroke or TIA 8 (14.0%) 2 (13.4%) 2 (13.3%) 2 (15.4%) 2 (14.3%)
Smoking 26 (45.6%) 10 (66.7%) 6 (40.0%) 6 (46.2%) 4 (28.6%)
Alcohol intake [units per week] 1.0 [0.0, 7.0] 1.0 [0.0, 5.0] 1.0 [0.0, 7.0] 1.0 [0.0, 9.0] 3.5 [0.0, 10.0]
Patient status
mRS, baseline [/6] 1.0 [0.0, 1.0] 1.0 [0.0, 2.0] 1.0 [1.0, 1.0] 1.0 [1.0, 1.0] 1.0 [0.0, 1.0]
Current NIHSS [/42] 0.0 [0.0, 1.0] 0.0 [0.0, 1.0] 0.0 [0.0, 1.0] 0.0 [0.0, 1.0] 0.5 [0.0, 1.0]
Cognition
MoCA (/30) 25.8 (2.4) 25.5 (2.9) 27.0 (1.7) 25.2 (2.2) 25.4 (2.6)
TMT part B (secs) 101.1 (74.7) 84.9 (44.2) 77.0 (32.3) 141.1(101.5) 107.3 (93.3)
TMT part B (points)⁎ 23.5 (4.1) 24.7 (0.7) 24.3 (0.9) 21.2 (6.9) 23.4 (4.5)
NART (error score) 18.0 (12.7) 16.8 (9.2) 14.3 (9.7) 20.4 (16.1) 21.0 (15.2)
Investigator reported scan information
SVD score MRI (/4) 1.2 (1.0) 1.6 (1.3) 0.9 (0.6) 1.0 (0.0) 1.3 (1.3)
SVD score CT (/2) 0.9 (0.8) 0.7 (0.8) 0.9 (0.7) 1.3 (0.9) 0.8 (0.8)
Centrally adjudicated scan information
Scan type, MRI 44 (77.2%) 13 (86.7%) 14 (93.3%) 7 (53.8%) 10 (71.4%)
Visible acute stroke lesion MRI 36 (81.8%) 9 (69.2%) 11 (78.6%) 6 (85.7%) 10 (100.0%)
SVD score MRI (/4) 1.8 (1.2) 1.9 (1.2) 1.4 (1.2) 2.1 (0.7) 2.1 (1.5)
≥ 1 lacune 27 (61.4%) 10 (76.9%) 6 (42.9%) 4 (57.1%) 7 (70.0%)
≥ 1 microbleeds 7 (17.9%) 2 (18.2%) 1 (7.7%) 1 (16.7%) 3 (33.3%)
Perivascular spaces 26 (59.1%) 7 (53.8%) 8 (57.1%) 5 (71.4%) 6 (60.0%)
WML Fazekas MRI 19 (43.2%) 6 (46.2%) 4 (28.6%) 4 (57.1%) 5 (50.0%)
Scan type, CT 13 (22.8%) 2 (13.3%) 1 (6.7%) 6 (46.2%) 4 (28.6%)
Visible acute stroke lesion CT 10 (76.9%) 2 (100.0%) 1 (100.0%) 4 (66.7%) 3 (75.0%)
Side of brain, left 5 (50.0%) 1 (50.0%) 1 (100.0%) 1 (25.0%) 2 (66.7%)
SVD score CT (/2) 0.9 (0.9) 0.5 (0.7) 1.0 (–) 1.5 (0.8) 0.3 (0.5)
≥ 1 lacune 6 (46.2%) 0 1 (100.0%) 4 (66.7%) 1 (25.0%)
WML Fazekas CT⁎ 6 (46.2%) 1 (50.0%) 0 5 (83.3%) 0
Note: If a participant had both a CT and MRI centrally reviewed then the results of the MRI are used for analysis. ISMN= isosorbide mononitrate; BP = blood pressure; TIA = transient
ischaemic stack; mRS=modiﬁed Rankin Scale; NIHSS= National Institutes of Health Stroke Scale; MoCA=Montreal Cognitive Assessment; NART=National Adult Reading Test; TMT
= trail making test; SVD = small vessel disease; MRI = magnetic resonance imaging; WML = white matter hyperintensities.
⁎ Signiﬁcant difference between the treatment groups (p b 0.05), comparisons done using Chi-square and Kruskal–Wallis tests.
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There were ten Serious Adverse Events (SAEs), six mild and four of
moderate severity, three possibly and the rest deﬁnitely or probably
not related to trial drugs (Supplementary Tables S1 and S2). There
was one recurrent ischaemic stroke in the ‘dual drugs immediate’
group and one TIA in the ISMN group. There were no deaths or major
haemorrhages and no SAEs in the cilostazol group.4.5. Cerebrovascular Reactivity and SVD Lesion Change, Participants in
Edinburgh
Of 28 participants randomised in Edinburgh, one chose not to partic-
ipate in the MRI sub-study, one did not complete MRI due to claustro-
phobia and two received insufﬁcient CO2 challenge due to problems
with gas delivery, leaving 24 participants with complete CVR data to as-
sess change. The groups were well balanced for demographic and neu-
roimaging characteristics (Supplementary Table S3), with mean age
67.5 (range 53–83) and 13/24 were male (56%).
CVR increased more between baseline and follow-up in those allo-
cated cilostazol or ISMN compared with those allocated delayed start
(whowere taking no drug at the follow-up CVR examination) although
the difference was not signiﬁcant (Kruskal–Wallis, p = 0.18), Fig. 4a.Please cite this article as: G.W. Blair, J.P. Appleton, K. Flaherty, et al., Tolerab
isosorbide mononitra..., , https://doi.org/10.1016/j.eclinm.2019.04.001Final CVR values were higher in participants taking any versus no trial
drug (Fig. 4b) although thedifferencewasnot signiﬁcant (Kruskal–Wal-
lis, p = 0.16).
Compared with baseline, the T2/FLAIR structural MRI at follow-up
showed a decline in WML in participants allocated cilostazol (WML re-
duced in 5/12 participants) versus no cilostazol (no change), Chi-square
p= 0.007. In participants allocated to ISMN,WML reduced in 3/13 ver-
sus in 2/13 in participants allocated to no ISMN, Chi-square p= 0.62. In
addition, onemicrobleed disappeared in a participant allocated to ISMN
and two lacunes appeared, both in participants allocated ‘dual drugs im-
mediate start’.
5. Discussion
LACI-1 tested short-term administration of cilostazol and ISMN,
alone and in combination, in patients with lacunar ischaemic stroke.
The drugs and doses were well-tolerated and dose escalation was feasi-
ble. Most participants, including those in the dual drug groups, were
taking target, or near to target dose, by the end of the treatment period.
Symptoms such as headache, palpitations, nausea were common both
off and on, either or both, trial medications, with no evidence of
sustained increase in symptoms on target dose, or of any difference be-
tween groups allocated single or dual drugs. Therewere nodrug-related
adverse events or bleeding complications, despite all participants alsoility, safety and intermediary pharmacological effects of cilostazol and
Table 2
Outcomes at week 8. All analyses are adjusted for baseline age, mean SBP, time from onset to randomisation and SVD total. Adjustment for other baseline covariates is included where
stated. For SVD total, the central scan readings were used and MRI was chosen over CT if both were available.
Both delayed
N = 14
ISMN
N = 15
Cil
N = 13
Both
immediate
N = 14
Cilostazol vs. no Cil
(2 + 3 v 1 + 4a)
ISMN vs. no ISMN
(1 + 3 v 2 + 4a)
Cil + ISMN vs. Cil alone
or ISMN alone
(3 + 4 v 1 or 2)
Week 3
(4a)
Week 8
(4)
Week 8
(1)
Week 8
(2)
Week 8
(3)
OR/MD
(95%CI)
p-Value OR/MD
(95%CI)
p-Value OR/MD
(95%CI)
p-Value
Primary outcome
On target dose week 8 (%) NA 5
(35.7%)
8
(53.3%)
3
(23.1%)
5 (35.7%) 0.39 (0.11,
1.34)
0.136 3.77 (0.98,
14.46)
0.053 0.84 (0.27,
2.64)
0.769
On partial dose (≥ 1/2 tablets) week 8
(%)
NA 4
(28.6%)
5
(33.3%)
6
(46.2%)
4 (28.6%) 1.68 (0.48,
5.83)
0.414 0.49 (0.13,
1.79)
0.280 0.51 (0.15,
1.71)
0.277
On partial dose (b1/2 tablets) week 8
(%)
NA 2
(14.3%)
0 0 3 (21.4%) 2.37 (0.31,
18.33)
0.408 1.40 (0.18,
11.00)
0.748 NC NC
Taking no tablets on week 8 (%) NA 3
(21.4%)
2
(13.3%)
4
(30.8%)
2 (14.3%) 1.00 (0.19,
5.22)
0.997 0.26 (0.04,
1.46)
0.125 0.86 (0.19,
3.92)
0.847
Secondary outcomes
Patients with symptom
Headache (%) 3
(21.4%)
4
(28.6%)
4
(26.7%)
1 (7.7%) 1 (7.1%) 0.29 (0.05,
1.76)
0.178 0.93 (0.18,
4.81)
0.928 1.26 (0.26,
6.18)
0.774
Nausea (%) 1 (7.1%) 3
(21.4%)
1 (6.7%) 2
(15.4%)
3 (21.4%) 5.07 (0.58,
44.42)
0.143 1.24 (0.18,
8.74)
0.828 2.81 (0.51,
15.34)
0.234
Loose stools (%) 5
(35.7%)
4
(28.6%)
0 2
(15.4%)
4 (28.6%) 1.43 (0.35,
5.88)
0.623 0.39 (0.08,
1.90)
0.242 7.07 (1.07,
46.66)
0.042
Bleeding (%) 2
(14.3%)
0 3
(20.0%)
2
(15.4%)
2 (14.3%) 1.05 (0.18,
6.26)
0.959 0.36 (0.06,
2.29)
0.281 0.25 (0.03,
1.98)
0.189
Peripheral haemodynamics, adjusted for
baseline
Systolic (mm Hg), mean (SD) 134.8
(12.4)
131.4
(19.0)
144.1
(16.5)
146.7
(19.4)
139.9
(20.7)
−1.1 (−8.4,
6.2)
0.77 −1.1 (−8.5,
6.4)
0.78 −4.9
(−11.7, 1.9)
0.16
Average of systolic & diastolic (mm
Hg), mean (SD)
107.6
(10.6)
104.7
(14.0)
114.5
(11.1)
114.0
(13.2)
109.9
(14.7)
−1.1 (−6.3,
4.1)
0.67 −0.7 (−6.0,
4.6)
0.79 −3.6 (−8.4,
1.2)
0.14
Diastolic (mm Hg), mean (SD) 80.4
(9.7)
78.0
(10.8)
84.9
(7.6)
81.3
(11.2)
79.8 (10.5) −1.6 (−5.8,
2.6)
0.45 −0.7 (−5.0,
3.7)
0.77 −2.6 (−6.5,
1.4)
0.20
Heart rate (bpm), mean (SD) 74.3
(9.3)
79.5
(11.2)
74.7
(12.5)
80.6
(15.0)
84.8 (15.1) 6.4 (1.2, 11.7) 0.02 0.1 (−5.5,
5.6)
0.98 3.1 (−1.9,
8.2)
0.23
Platelet function, adjusted for baseline
ADP median ﬂuorescence, mean (SD) 519.3
(234.5)
502.1
(242.8)
454.9
(238.8)
518.9
(179.5)
451.7
(176.5)
−1.3 (−77.6,
75.0)
0.97 −0.5 (−80.1,
79.1)
0.99 11.9 (−60.2,
84.1)
0.75
AA median ﬂuorescence, mean (SD) 741.0
(395.0)
775.4
(474.4)
675.2
(364.1)
636.4
(272.4)
679.6
(376.6)
−83.6 (−
256.5, 89.4)
0.34 −14.1 (−
192.5, 164.2)
0.88 109.7
(−54.0,
273.5)
0.19
Unstimulated median ﬂuorescence,
mean (SD)
87.0
(29.0)
80.4
(29.1)
86.1
(29.0)
75.9
(27.3)
83.7 (33.8) −2.9 (−15.1,
9.3)
0.64 −8.2 (−20.7,
4.2)
0.20 7.5 (−4.0,
19.0)
0.20
Hb (g/L), week 8, adjusted for
baseline, mean (SD)
133.0
(12.2)
136.2
(13.5)
146.9
(12.0)
130.8
(9.5)
137.1
(14.6)
−3.7 (−8.4,
1.0)
0.12 −1.0 (−6.9,
4.4)
0.73 −2.4 (−6.8,
2.1)
0.30
Platelet count, week8, adjusted for
baseline, mean (SD)
260.3
(47.1)
258.4
(56.1)
238.6
(45.5)
289.5
(61.4)
284.3
(57.8)
35.7 (2.8,
68.7)
0.03 3.9 (−32.4,
40.2)
0.83 −7.4
(−36.8,
21.9)
0.62
Central arterial pressure waveform
analysis, adjusted for baseline
Pulse wave velocity m/s, mean (SD) 16.8
(7.5)
23.2
(11.9)
18.6
(11.3)
17.9
(8.1)
18.6 (8.5) −0.4 (−5.1,
4.4)
0.89 1.1 (−3.7,
5.9)
0.66 −0.8 (−5.3,
3.6)
0.72
Pulse wave analysis
Augmentation index 75 (%), mean
(SD)
24.0
(10.6)
16.2
(12.4)
17.5
(12.9)
23.0
(10.6)
14.7 (10.5) −4.8 (−9.7,
0.2)
0.06 −4.7 (−9.8,
0.3)
0.07 0.1 (−4.8,
4.9)
0.97
Central blood pressure, mean (SD) 99.0
(14.6)
95.4
(12.7)
101.2
(12.4)
103.1
(11.8)
98.8 (11.7) −2.0 (−8.2,
4.2)
0.52 −4.7 (−10.7,
1.2)
0.12 −3.4 (−9.1,
2.4)
0.25
Buckberg viability ratio, mean (SD) 154.4
(21.5)
164.8
(22.2)
166.6
(25.2)
152.2
(31.4)
132.9
(22.7)
−10.8
(−21.2,
−0.5)
0.04 6.8 (−4.0,
17.1)
0.20 −11.4
(−21.0,
−1.7)
0.02
Cognition (TMT), adjusted for baseline
TMT A — time, mean (SD) 39.5a
(15.1)
37.8
(16.8)
33.5
(10.3)
51.1
(33.5)
31.9 (9.2) −4.0 (−12.7,
4.7)
0.37 −4.2 (−12.8,
4.4)
0.34 −5.6
(−13.4, 2.3)
0.17
TMT A — points, mean (SD) 24.9a
(0.4)
23.1
(6.7)
25.0
(0.0)
21.2
(9.4)
24.9 (0.3) −1.1 (−3.6,
1.5)
0.41 2.6 (0.1, 5.1) 0.05 0.3 (−2.1,
2.7)
0.81
TMT B — time, mean (SD) 84.9a
(44.2)
79.9
(34.4)
76.9
(39.4)
114.3
(63.1)
84.3 (50.4) −3.4 (−22.7,
16.0)
0.73 −3.1 (−22.4,
16.3)
0.76 −2.3
(−20.2,
15.6)
0.80
TMT B — points, mean (SD) 24.7a
(0.7)
22.9
(6.6)
24.7
(0.8)
19.4
(9.3)
22.9 (4.1) −2.2 (−5.1,
0.7)
0.14 2.3 (−0.7,
5.3)
0.13 −0.2 (−3.0,
2.60)
0.89
SVD = small vessel disease; MRI = magnetic resonance imaging; ISMN= isosorbide mononitrate; Cil = cilostazol; OR = odds ratio; HR= Hazard ratio; MD=mean difference; CI =
conﬁdence interval; NA = not applicable; SD = standard deviation; ADP = adenosine diphosphate; AA= arachidonic acid; Hb = haemoglobin; TMT= trail making test.
a Week 0 values.
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Fig. 2. Tablet compliance: Proportion of participantswhowere taking full dose combinedwith the proportion taking ≥1/2 tablets into one group, (solid lines, labelled ‘full dose’) noting that
missing even one dose was counted as ≥1/2 tablets). The combined and delayed groups from week 5 onwards had very close numbers and so the lines appear on top of each other. The
dotted lines show those who had taken no tablets at all that week. More details of compliance by number of missed doses is given in Fig. S2. ISMN= isosorbide mononitrate.
Fig. 3. Symptoms of headache, palpitations, dizziness, loose stools, and nausea. ISMN = isosorbide mononitrate.
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Fig. 4. Cerebrovascular reactivity (CVR). a) Change in white matter CVR by allocated treatment group (difference between groups, Kruskal–Wallis, p = 0.18). b) Change in white matter
CVR in participants taking half target dose or greater of any allocated treatment versus those taking no or less than half dose (difference between groups, Kruskal–Wallis, p = 0.16).
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phosphodiesterase 3′ inhibitor cilostazol act on relevant target mecha-
nisms [3] based on current knowledge of human sporadic SVD [1], and
are licenced agents with established safety proﬁles. LACI-1 showed
that both drugs affect systemic haemodynamic function, and may im-
prove vasoreactivity in white matter, reduceWML, and improve cogni-
tive performance, all ofwhich require conﬁrmation in larger trials. LACI-
1 demonstrates drug tolerability and supports testing of ISMN and
cilostazol in larger trials with clinical endpoints.
Data on nitrates in patients with lacunar stroke, or other SVD mani-
festations, are limited [9]. In the Efﬁcacy of Nitric Oxide in Stroke (ENOS)
Trial, seven days of GTN improved cognitive test scores at 90 days if
started within 6 h of acute stroke [7], lowered BP and its variability in
acute lacunar syndromes, and improved early neurological outcome in
those with a conﬁrmed acute lacunar infarct. NO donors could improve
vasoreactivity (which is impaired in lacunar stroke [19]), are neuropro-
tective and anti-inﬂammatory [3], all relevant targets in SVD [1]. Such
effects could explain improvements in WML, cognition, systemic
haemodynamics and cerebral vasoreactivity suggested in LACI-1 and
are worth testing in larger trials. Alternatively, the reduction in WML
seen in some patients could reﬂect themodest blood pressure reduction
seen in the trial, although whether such effects could occur in a few
weeks is unknown. Data on other vasoactive drugs in SVD are limited.
In post-hoc analyses, patients who experienced headache soon after
starting dipyridamole for secondary stroke prevention had fewer recur-
rent strokes than those without headache [20], suggesting that head-
ache may be a useful indicator of improved cerebrovascular reactivity
which may help prevent further stroke.
Trials testing cilostazol for secondary stroke prevention include over
6000 patients in Korea, Japan or China, but focused on short-term stroke
prevention after ischaemic stroke [11], with limited data on symptoms
or tolerance rates and only one small study on platelet function [21].Please cite this article as: G.W. Blair, J.P. Appleton, K. Flaherty, et al., Tolerab
isosorbide mononitra..., , https://doi.org/10.1016/j.eclinm.2019.04.001Cilostazol has weak antiplatelet effects and therefore low bleeding risk
[22]. Trials testing cilostazol to prevent cognitive decline are ongoing
[23], and routinely prescribed cilostazol was associated with fewer inci-
dent dementias in a large Taiwanese health data registry, in a ‘dose re-
sponse’ manner [13]. Short-term cilostazol improved cerebrovascular
pulsatility [24]. There are no data on tolerance or stroke prevention in
Western populations and limited data in peripheral vascular disease
[10]. Differences in SVD prevalence, diet, lifestyle and risk factor expo-
sures preclude direct generalisation from Asia-Paciﬁc toWestern popu-
lations [25]. In experimental models, cilostazol unblocks endothelial-
dysfunction induced oligodendrocyte precursor cell maturation, thus
improving myelin formation and repair and sustaining axons [26], re-
duces oxidative stress, attenuatesmicroglial activation andWML forma-
tion [27,28], and improves amyloid-β clearance [29]. These pleiotropic
effects would be beneﬁcial if translated to human sporadic SVD, and
could explain improvements in cognition, cerebrovascular reactivity
and reduction in WML suggested in LACI-1 and should be tested in fu-
ture trials.
5.1. Limitations
LACI-1 limitations include its small size, short-termdrug administra-
tion and limited clinical endpoints. The size limited analysis of whether
drug effects differed by lacunar clinical syndrome, but could be tested in
future trials.Weused the Trails A and B tests of cognitive functionwhich
may be prone to practice effects but this will affect all uses of these stan-
dard tests. The minimisation algorithmwas imperfect since there was a
baseline imbalance in age, reﬂected in the WML and cognitive scores.
The combined drugs were better tolerated than expected. There was
no formal ‘no drug’ control group throughout the trial, although there
was the ‘drug-free period’ in the ‘dual drug, delayed start’ group.
There were no previous data available on initiation of both drugsility, safety and intermediary pharmacological effects of cilostazol and
9G.W. Blair et al. / EClinicalMedicine xxx (xxxx) xxxtogether, therefore for dual administration,we integrated thedose esca-
lation usually used for each drug. Slow dose escalation of dipyridamole
and aspirin did not reduce headache, in comparisonwith standard dose
escalation, although may have improved adherence [30]. Since the
doses for licenced indications are somewhat arbitrary andwide ranging,
it is reasonable to think that half dose would have some effect on the
target mechanisms, and can be tested a priori in larger trials. Patients
could enter the trial with CT or MRI brain imaging, thus achieving faster
recruitment at lower expense than just using MRI, while ensuring
generalisability. We estimate that the trial would have taken eight
months (50%) longer and cost £85,000 (33%) extra with mandatory
MRI. The ﬂexible imaging entry criteria did not allow assessment of
causes of lacunar stroke such as branch atheromatous disease; this
could be assessed in future trials, but requirement for detailed MRI
might reduce recruitment.
5.2. Conclusions
LACI-1 suggests that patients can be randomised to ISMN and
cilostazol in addition to guideline secondary stroke prevention includ-
ing single antiplatelet agents. LACI-1 indicates that LACI-2
(ISRCTN14911850), a partial-factorial prospective randomised open-
label blinded endpoint trial, aiming to randomise 400 patients, should
proceed, to assess these medications' effects on stroke recurrence, cog-
nitive function, neuropsychiatric symptoms, progression of SVD and
safety in patients with lacunar stroke, and feasibility for large deﬁnitive
trial.
Data Sharing
The data are available from the authors.
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